Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Combined Oral Contraceptive (COC)

Approved

PPenn State University

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

OtherActive, not recruiting

OtherApproved

Active, not recruiting

Timeline

Expected Milestones

Q4 2028

ApprovedActive, not recruiting

Other

NCT02367846

Clinical

Trials by Indication[1]

Cornea1 trial

Corneal Topography and High Order Aberrations in Women on Regular Contraceptive Pills

Completed·EElshimaa A.Mateen··NCT07693673·40 enrolled

Other1 trial

The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology

Active, not recruiting·PPenn State University·Approved·NCT02367846·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Combined Oral Contraceptive (COC). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Combined Oral Contraceptive (COC). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Penn State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: PPenn State University

Related News